AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$ARQT

Welgus Howard G. sold $124K of ARQT

Welgus Howard G. sold 4,730 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.18 ($0.12M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Welgus Howard G.
Published Aug 19, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The modest size and pre‑arranged 10b5‑1 plan suggest limited informational content for traders.

02

Market read

Minor insider sale with negligible trading impact.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: post-filing 2026-08-19

Background

Form 4 filings disclose insider transactions; this is a routine director sale.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Director Welgus Howard G. sold 4,730 shares of ARQT for $123,834 via a 10b5-1 plan.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

The transaction amount is small relative to float and typical insider activity, so market reaction is expected to be minimal.

Market effects

Sector

No immediate sector-wide implications; biotech sector remains unchanged.

Regional

US market only; no regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be purely portfolio rebalancing; investors might view it as non‑signal.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies.

  • Insider
    Welgus Howard G.

    Director of Arcutis Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

AUG 5
$ARQTHigh

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min